ZAFIRLUKAST

Post-LOE

zafirlukast

Aurobindo Pharma

ANDAORALTABLET

Approved

Nov 2023

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

5/8 — Partial

ZAFIRLUKAST (zafirlukast) by Aurobindo Pharma is leukotriene receptor antagonists [moa]. Approved for leukotriene receptor antagonist [epc]. First approved in 2023.

Drug data last refreshed 18h ago

$0.0BPart D

Mechanism of Action

Leukotriene Receptor Antagonists

Pharmacologic Class:

Leukotriene Receptor Antagonist

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Clinical Trials (2)

NCT06069063Phase 2Not Yet Recruiting

Crossover Study of Zafirlukast in Preventing Allergen-induced Signs and Symptoms in Response to Cat Dander Challenge

Started Dec 2025

12 enrolled

Allergy to Cats

NCT01283061Phase 1Completed

Bioequivalence Study of Zafirlukast Tablets 20 mg of Dr. Reddy's Laboratories Limited Under Fasting Condition

Started Dec 2007

44 enrolled

Healthy

Company

Worked on ZAFIRLUKAST at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.